公开(公告)号：US20230355756A1

公开(公告)日：2023-11-09

申请号：US18245533

申请日：2021-08-06

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Robin Barbour ,  Gene Kinney ,  Wagner Zago

IPC: A61P37/04 ,  A61K39/395

CPC classification number: A61K39/3955 ,  A61P37/04 ,  A61K2039/6037

Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of neurodegenerative diseases, such as Parkinson’s disease, dementia with Lewy bodies (DLB), Alzheimer’s disease or other synucleinopathies, with alpha-synuclein deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of alpha-synuclein, blocking the uptake by neurons and inhibiting propagation of alpha-synuclein seeds in a subject having or at risk of developing a neurodegenerative disease containing alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising alpha-synuclein peptide.

公开(公告)号：US10889638B2

公开(公告)日：2021-01-12

申请号：US16091060

申请日：2017-05-02

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Robin Barbour ,  Philip James Dolan, III ,  Yue Liu ,  Svetlana Alexander ,  Mark E. Renz

IPC: C07K16/18 ,  G01N33/68

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US10889636B2

公开(公告)日：2021-01-12

申请号：US15918937

申请日：2018-03-12

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Stephen Jed Tam ,  Yue Liu ,  Robin Barbour ,  Theodore Yednock ,  Kenneth Flanagan

IPC: A61K47/68 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin α4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.

公开(公告)号：US10852309B2

公开(公告)日：2020-12-01

申请号：US15247598

申请日：2016-08-25

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Robin Barbour ,  Lynn R. Zieske ,  Sarah Hamren

IPC: G01N33/68 ,  C07K16/18 ,  G01N33/50 ,  G01N33/58 ,  G01N33/543

Abstract: The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.

公开(公告)号：US10669331B2

公开(公告)日：2020-06-02

申请号：US16385968

申请日：2019-04-16

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Robin Barbour ,  Kate Dora Games Thiel ,  Tarlochan S. Nijjar

IPC: C07K16/18 ,  C07K19/00 ,  A61K49/00 ,  A61K39/00 ,  G01N33/68

Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).

公开(公告)号：US20190315843A1

公开(公告)日：2019-10-17

申请号：US16385968

申请日：2019-04-16

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Robin Barbour ,  Kate Dora Games Thiel ,  Tarlochan S. Nijjar

IPC: C07K16/18 ,  A61K49/00

Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).

公开(公告)号：US20170158755A1

公开(公告)日：2017-06-08

申请号：US15125569

申请日：2015-03-12

Applicant: PROTHENA BIOSCIENCES LIMITED

Inventor： Kenneth Flanagan ,  Stephen Jed Tam ,  Yue Liu ,  Theodore Yednock ,  Robin Barbour

IPC: C07K16/18

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides antibodies that specifically bind to the LG1-3 modules of the G domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to MCAM. The antibodies can be used for inhibiting undesired immune responses, treatment of cancer, or treatment of obesity or obesity-related diseases, among other applications.

公开(公告)号：US12195525B2

公开(公告)日：2025-01-14

申请号：US17937109

申请日：2022-09-30

Applicant: Prothena Biosciences Limited

Inventor： Peter Seubert ,  Philip James Dolan, III ,  Yue Liu ,  Robin Barbour

IPC: C07K16/18 ,  A61P25/28

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20240209073A1

公开(公告)日：2024-06-27

申请号：US18422712

申请日：2024-01-25

Applicant: Prothena Biosciences Limited

Inventor： Tarlochan S. Nijjar ,  Robin Barbour ,  Philip James Dolan, III ,  Yue Liu ,  Svetlana Alexander ,  Mark E. Renz

IPC: C07K16/18 ,  A61K9/00 ,  A61K45/06 ,  C12N15/63

CPC classification number: C07K16/18 ,  C12N15/63 ,  A61K9/0019 ,  A61K45/06 ,  C07K2317/565

Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

公开(公告)号：US20230340094A1

公开(公告)日：2023-10-26

申请号：US18305109

申请日：2023-04-21

Applicant: Prothena Biosciences Limited

Inventor： Peter Seubert ,  Philip James Dolan, III ,  Yue Liu ,  Robin Barbour

IPC: C07K16/18 ,  A61K47/68 ,  A61P25/28 ,  A61K39/00 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K47/6843 ,  A61K47/6803 ,  A61P25/28 ,  A61K39/0007 ,  G01N33/6896 ,  C07K2317/24 ,  C07K2317/92 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/34 ,  C07K2317/55 ,  G01N2333/47 ,  G01N2800/2821

Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.